Metabotropic Glutamate Receptor 3 mGluR3 or GRM3 or GPRC1C or MGLUR3-Pipeline Review, H1 2016

Metabotropic Glutamate Receptor 3 mGluR3 or GRM3 or GPRC1C or MGLUR3-Pipeline Review, H1 2016


  • Products Id :- GMDHC0090TDB
  • |
  • Pages: 37
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3)-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3)-Pipeline Review, H1 2016', provides in depth analysis on Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) targeted pipeline therapeutics.

The report provides comprehensive information on the Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3)

The report reviews Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) targeted therapeutics and enlists all their major and minor projects

The report assesses Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) Overview 6

Therapeutics Development 7

Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3)-Products under Development by Stage of Development 7

Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3)-Products under Development by Therapy Area 8

Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3)-Products under Development by Indication 9

Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3)-Pipeline Products Glance 10

Early Stage Products 10

Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3)-Products under Development by Companies 11

Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3)-Products under Development by Universities/Institutes 13

Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3)-Therapeutics Assessment 15

Assessment by Monotherapy/Combination Products 15

Assessment by Mechanism of Action 16

Assessment by Route of Administration 18

Assessment by Molecule Type 19

Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3)-Companies Involved in Therapeutics Development 20

Addex Therapeutics Ltd 20

Domain Therapeutics SA 21

Medgenics, Inc. 22

Prexton Therapeutics SA 23

Taisho Pharmaceutical Holdings Co., Ltd. 24

Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3)-Drug Profiles 25

DT-011088-Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

fasoracetam-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

MGS-0028-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Small Molecules to Agonize mGluR3 for Parkinson's Disease-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Small Molecules to Antagonize mGluR3 for Anxiety and Depression-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Small Molecules to Modulate mGlu3 Receptor for CNS Disorders-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

VU-0092273-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3)-Dormant Projects 32

Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3)-Discontinued Products 34

Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3)-Featured News & Press Releases 35

Apr 14, 2014: Domain Therapeutics continues program to alter course of Parkinson's disease with renewed support by The Michael J. Fox Foundation 35

Appendix 36

Methodology 36

Coverage 36

Secondary Research 36

Primary Research 36

Expert Panel Validation 36

Contact Us 36

Disclaimer 37

List of Figures

Number of Products under Development for, H1 2016 7

Number of Products under Development by Therapy Area, H1 2016 8

Number of Products under Development by Top 10 Indication, H1 2016 9

Comparative Analysis by Early Stage Products, H1 2016 10

Assessment by Monotherapy/Combination Products, H1 2016 15

Number of Products by Mechanism of Actions, H1 2016 16

Number of Products by Stage and Mechanism of Actions, H1 2016 16

Number of Products by Stage and Routes of Administration, H1 2016 18

Number of Products by Stage and Molecule Type, H1 2016 19

List of Tables

Number of Products under Development for, H1 2016 7

Number of Products under Development by Therapy Area, H1 2016 8

Number of Products under Development by Indication, H1 2016 9

Comparative Analysis by Early Stage Products, H1 2016 10

Number of Products under Development by Companies, H1 2016 11

Products under Development by Companies, H1 2016 12

Number of Products under Investigation by Universities/Institutes, H1 2016 13

Products under Investigation by Universities/Institutes, H1 2016 14

Assessment by Monotherapy/Combination Products, H1 2016 15

Number of Products by Stage and Mechanism of Action, H1 2016 17

Number of Products by Stage and Route of Administration, H1 2016 18

Number of Products by Stage and Molecule Type, H1 2016 19

Pipeline by Addex Therapeutics Ltd, H1 2016 20

Pipeline by Domain Therapeutics SA, H1 2016 21

Pipeline by Medgenics, Inc., H1 2016 22

Pipeline by Prexton Therapeutics SA, H1 2016 23

Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H1 2016 24

Dormant Projects, H1 2016 32

Dormant Projects (Contd..1), H1 2016 33

Discontinued Products, H1 2016 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Addex Therapeutics Ltd

Domain Therapeutics SA

Medgenics, Inc.

Prexton Therapeutics SA

Taisho Pharmaceutical Holdings Co., Ltd.

Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) Therapeutic Products under Development, Key Players in Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) Therapeutics, Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) Pipeline Overview, Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) Pipeline, Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) Pipeline Assessment

select a license

Single User License
USD 3500 INR 224070
Site License
USD 7000 INR 448140
Corporate User License
USD 10500 INR 672210

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com